Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science



Rating:

Share or cite this content

Citations should be made in the following way:
I. Hoof (Hørsholm, Denmark), K. Bønnelykke (Copenhagen, Denmark), M. Witten (Hørsholm, Denmark), T. Stranzl (Hørsholm, Denmark), X. Li (Tucson, United States of America), D. Meyers (Tucson, United States of America), E. Bleecker (Tucson, United States of America), P. Andersen (Hørsholm, Denmark). Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma. 1483

Member's Comments

No comment yet.

Related content which might interest you: Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006 Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005 Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases Year: 2019 Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002 Polymorphisms of IL-4/IL4R alpha genes in house dust mite allergic asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 141s Year: 2005 OPURIT: Omalizumab-protected ultra rush specific immunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 Association between dust mite sensitisation and asthma severity Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010 Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 590s Year: 2005 Calcaratarin D attenuates house dust mite-induced allergic asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 The effect of anti-mite mattress covers on mite allergen levels in the PIAMA (prevention and incidence of asthma and mite allergy) study Source: Eur Respir J 2001; 18: Suppl. 33, 321s Year: 2001 Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001 Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006 High-altitude treatment in atopic and nonatopic patients with severe asthma Source: Eur Respir J 2012; 40: 1374-1380 Year: 2012